Adicet Bio Inc expected to post a loss of $2.03 a share - Earnings Preview

ADICET Bio

03/08/2026 12:36

Adicet Bio Inc ACET.OQ ACET.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Adicet Bio Inc is for a loss of $2.03 per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Adicet Bio Inc is $22.50, about 147% above its last closing price of $9.11
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-3.07
-3.11
-1.88
Beat
39.6
Dec. 31 2026
-3.28
-2.80
-2.94
Missed
-4.9
Sep. 30 2025
-4.67
-4.64
-4.64
Met
-0.1​
Jun. 30 2025
-5.03
-4.87
-5.44
Missed
-11.7
​​Mar. 31 2025
-5.25
-5.31
-4.96
Beat
6.5
Dec. 31 2024
-5.80
-5.79
-5.12
Beat
11.6​
Sep. 30 2024
-5.55
-5.45
-5.44
Beat
0.1
Jun. 30 2024
-5.81
-5.82
-5.28
Beat
9.3
This summary was machine generated August 3 at 11:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)